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INTRODUCTION
1INTRODUCTION62
Diseases of the gastrointestinal tract are common among those
who are HIV – infected. Sometimes the first clue that a previously
undiagnosed patient is HIV-infected is the presence of a HIV-
associated gastrointestinal condition. These conditions can lead to
significant morbidity including pain, difficulty in swallowing, diarrhea,
and weight loss. Early diagnosis and treatment can substantially
improve the lives of those who are afflicted by these conditions.
Although identifying the specific etiology of a patient’s symptoms can
be challenging, a methodical approach can usually identify a treatable
condition.
ORAL LESIONS:
The most common HIV-associated oral condition is candidiasis,
or thrush. Thrush is usually found in those with advanced
immunodeficiency, generally in patients with a CD4+ T cell count less
than 300 cells/mm3. Oral candidiasis is associated with progression to
AIDS, and the presence of thrush in someone who is not known to be
HIV infected should prompt a recommendation for HIV testing.
2Oral hairy leukoplakia (OHL): Thought to be due to Epstein-Barr
virus, the lesions are asymptomatic and are generally of only cosmetic
importance. OHL sometimes responds to acyclovir or valacyclovir,
although probably the best treatment is HAART induced immune
reconstitution. As with thrush, OHL is highly predictive of HIV.
Aphthous ulcers are common and often severe in those who are
HIV infected.
Oral  lesions that  do not  heal  within two weeks or  those that  are
accompanied by systemic signs such as fever should be biospied to rule
out other etiologies such as deep fungal infection or malignancy.
Single shallow painless ulcerations can be due to syphilis
(condyloma lata), and should be screened for with a rapid plasma reagin
(RPR) test.
Warts can be found on the lips or in the oral cavity and are
typically painless. Kaposi’s sarcoma (KS) can be found any where in
the GI tract.
ESOPHAGEAL LESIONS:
Disease involving the esophagus is common in advanced HIV
infection, and is most commonly due to Candida.  Patients with
3candidal esophagitis usually have oropharyngeal involvement as well
and present with dysphagia and odynophagia.
In cases of esophagitis that fail to respond to antifungal therapy,
endoscopy with biopsy is required to rule out other etiologies such as
herpes simplex virus (HSV), cytomegalovirus (CMV), malignancy, or
aphthous ulcerations.
DIARRHEA:
World wide, diarrhea is the most common cause of morbidity and
mortality among those who are HIV - infected. Diarrhea can be caused
by bacterial, viral or parasitic infections, or by a medication.
The evaluation of a patient with diarrhea begins with a thorough
history and physical examination.
In patients with advanced immunodeficiency, fever, and anemia,
opportunistic infections such as those caused by Mycobacterium avium
complex (MAC) and CMV must be considered.
In those who present with symptoms of greater than one-week
duration associated with weight loss, fever, dehydration, or bloody
stools, diagnostic studies are indicated.
4The most common bacterial causes of diarrhea are Salmonella, C.
difficile, MAC, shigella, and Campylobacter. The overall incidence of
bacterial colitis has been reduced by the widespread use of
trimethoprim / sulfamethoxazole (TMP/FMX) for Pneumocystis
prophylaxis.
Common parasitic causes of diarrhea include Cryptosporidium,
Microsporidium and Entamoeba histolytica.
Diarrhea due to rotavirus or other viral agents is relatively
common but is usually self-limited.
In those with advanced immunosuppression (typically CD4
counts of <50/mm3) CMV can lead to colitis, but since the introduction
of HAART, the incidence of active CMV disease has fallen
dramatically.
Histoplasmosis can involve the gastrointestinal tract, leading to
diarrhea, fever, pain, and weight loss. Diagnosis can be made by the
detection of intracellular budding yeast in colonic biopsy specimens.
The histoplasmosis urinary antigen is very useful for diagnosing this
infection and for monitoring therapy.
5ANORECTAL DISEASE:
Both HSV1 and 2 commonly cause anorectal disease. HSV
infection can also lead to urinary symptoms, impotence, and sacral
paresthesias. In HIV-infected patients who present with perianal
ulcerative lesions or fissures, the most common cause is HSV.
Gonorrhea, syphilis, and chlamydia:
Patients who are infected with Neisseria gonorrhoea and
Chlamydia trachomatis can present with symptoms that include anal
discharge, pain, tenesmus, and  bleeding. Cultures of rectal swabs and
urine ligase chain reaction (LCR) for Gonorrhea and Chlamydia
infection can be useful in making the diagnosis.
Warts, caused by human papillomaviruses (HPV) are commonly
found in the perianal area.
AIMS  AND OBJECTIVES
6AIMS AND OBJECTIVES
To determine the association between CD4 count and GIT
manifestations.
To  evaluate  the  common  symptoms  and  etiology  of  GIT
manifestations.
REVIEW OF  LITERATURE
7REVIEW OF LITERATURE
WHO Clinical Staging of HIV for Adults and Adolescents with
Confirmed HIV Infection 58 :
The clinical staging and case definition of HIV for resource-
constrained settings were developed by the WHO in 1990 and revised
in 2007. Staging is based on clinical findings that guide the diagnosis,
evaluation and management of HIV/AIDS, and does not require a CD4
cell count. This staging system is used in many countries to determine
eligibility for antiviral therapy. Clinical stages are categorized as 1
through 4, progressing from primary HIV infection to advanced HIV /
AIDS. These stages are defined by specific clinical conditions or
symptoms. For the purpose of the WHO staging system, adolescents
and adults are defined as individuals aged >  15 years.
Table : 1
WHO Clinical Staging of established HIV infection
HIV ASSOCIATED SYMPTOMS WHO CLINICAL STAGE
Asymptomatic 1
Mild Symptoms 2
Advanced Symptoms 3
Severe Symptoms 4
8Clinical Stage 1
x Asymptomatic
x Persistent generalized lymphadenopathy
Clinical Stage 2
x Unexplained moderate weight loss (<10% of presumed or
measured body weighta)
x Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis
media and pharyngitis)
x Herpes zoster
x Angular cheilitis
x Recurrent oral ulceration
x Papular pruritic eruptions
x Seborrhoeic dermatitis
x Fungal nail infections
Clinical Stage 3
x Unexplainedb severe weight loss (>10% of presumed or
measured body weight)
x Recurrent chronic diarrhea for longer than one month
x Unexplained persistent fever (above 37.5o intermittent or
constant, for longer than one month)
9x Persistent oral candidiasis
x Oral hairy leukoplakia
x Pulmonary tuberculosis
x Severe bacterial
infections(eg,pneumonia,empyema,pyomyositis,bone or joint
infection, meningitis,bacteremia)
x Acute necrotizing ulcerative stomatitis,gingivitis or periodontitis
x Unexplained anaemia(<8 gm/dl),neutropenia (<0.5 x 10 9 per
liter) and / or chronic thrombocytopaenia (<50 x 10 9 per liter)
Clinical Stage 4 c
x HIV wasting syndrome
x Pneumocystis pneumonia
x Recurrent severe bacterial pneumonia
x Chronic herpes simplex infection (orolabial, genital or anorectal
of more than one month’s duration or visceral at any site)
x Oesophageal candidiasis (or candidiasis of trachea, bronchi or
lungs)
x Extrapulmonary tuberculosis
x Kaposi’s sarcoma
x Cytomegalovirus infection (retinitis or infection of other organs)
10
x Central nervous system toxoplasmosis
x HIV encephalopathy
x Extrapulmonary cryptococcosis including meningitis
x Disseminated non-tuberculous mycobacterial infection
x Progressive multifocal leukoencephalopathy
x Chronic cryptosporidiosis
x Chronic isosporiasis
x Disseminated mycosis (extrapulmonary histoplasmosis or
coccidioidomycosis)
x Recurrent septicaemia (including non-typhoidal Salmonella)
x Lymphoma (cerebral or B-cell non – Hodgkin)
x Invasive cervical carcinoma
x Atypical disseminated leishmaniasis
x Symptomatic HIV-associated nephropathy or symptomatic HIV-
associated cardiomyopathy
a- Assessment of body weight in pregnant woman needs to
consider the expected weight gain of pregnancy
b- Unexplained refers to where the condition is not explained by
other causes.
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c- Some additional specific conditions can also be included in
regional classifications (such as reactivation of American
trypanosomiasis (meningoencephalitis and / or myocarditis) in
the WHO Region of the Americas and penicilliosis in Asia).
Table : 2
CRITERIA FOR HIV STAGING EVENTS 59
Adults (15 years or older)
Clinical Event Clinical Diagnosis
Definitive
Diagnosis
Asymptomatic.  No HIV – related symptoms
reported and no signs on
examination.
Not applicable.
Persistent
generalized
lymphadenopathy.
Painless enlarged
lymphnodes > 1 cm in two
or more non – contiguous
sites (excluding inguinal) in
the absence of known cause
and persisting for three
months or more.
Histology.
Herpes zoster. Painful vesicular rash in
dermatomal distribution of a
nerve supply, does not cross
the midline.
Clinical diagnosis.
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Clinical Event Clinical Diagnosis
Definitive
Diagnosis
Unexplained
chronic diarrhea
for longer than
one month.
Chronic diarrhea (loose or
watery stools three or more
times daily) reported for
longer than one month.
Three or more stools
observed and
documented as
unformed, and two
or more stool tests
reveal no pathogens.
Unexplained
persistent fever
(intermittent or
constant and
lasting for longer
than one month).
Fever or night sweats for
more than one month, either
intermittent or constant with
reported lack of response to
antibiotics or antimalarial
agents, without other
obvious foci of disease on
examination; malaria must
be excluded in malarious
area.
Documented fever
>37.5°C with
negative blood
culture, negative
Ziehl-Neelsen stain,
negative malaria
slide, normal or
unchanged chest X-
ray and no other
obvious focus of
infection.
Persistent oral
candidiasis.
Persistent or recurring
creamy white curd-like
plaques that can be scarped
off (pseudomembranous) or
red patches on tongue,
palate or lining of mouth,
usually painful or tender
(erythematous form).
Clinical diagnosis.
Pulmonary
tuberculosis
Chronic symptoms: (lasting
at least 2-3 weeks) cough,
Isolation of
M.Tuberculosis on
13
Clinical Event Clinical Diagnosis
Definitive
Diagnosis
(current). haemoptysis, shortness of
breath, chest pain, weight
loss, fever, night sweats;
PLUS EITHER
Positive sputum smear;
OR
Negative sputum smear;
AND
Compatible chest radiograph
(including but not restricted
to upper lobe infiltrates,
cavitation, pulmonary
fibrosis).
No evidence of extra
pulmonary disease.
sputum culture or
histology of lung
biopsy (with
compatible
symptoms).
Severe bacterial
infection (such as
pneumonia,
meningitis,
empyema,
pyomyositis, bone
or joint infection,
bacteraemia and
severe pelvic
inflammatory
disease).
Fever accompanied by
specific symptoms or signs
that localize infection and
response to appropriate
antibiotic.
Isolation of bacteria
from appropriate
clinical specimens
(usually sterile
sites).
14
Clinical Event Clinical Diagnosis
Definitive
Diagnosis
Pneumocystis
pneumonia.
Dyspnoea on exertion or
nonproductive cough of
recent onset (within the past
three months), tachypnoea
and fever;
AND
Chest X-ray evidence of
diffuse bilateral interstitial
infiltrates;
AND
No evidence of bacterial
pneumonia; bilateral
crepitations on auscultation
with or without reduced air
entry.
Cytology or
immunofluorescent
microscopy of
induced sputum or
bronchoalveolar
lavage or histology
of lung tissue.
Chronic herpes
simplex virus
infection
(orolabial, genital
or anorectal) of
more than one
month or visceral
infection of any
duration.
Painful, progressive
anogenital or orolabial
ulceration; lesions caused by
recurrence of herpes
simplex virus infection and
reported for more than one
month. Hisory of previous
episodes. Visceral herpes
simplex virus requires
definitive diagnosis.
Positive culture or
DNA (by
polymerase chain
reaction) of herpes
simplex virus or
compatible cytology
or histology.
Oesophageal
condidiasis.
Recent onset of retrosternal
pain or difficulty on
Macroscopic
appearance at
15
Clinical Event Clinical Diagnosis
Definitive
Diagnosis
swallowing (food and
fluids) together with oral
candidiasis.
endoscopy or
bronchoscopy, or by
microscopy or
histology.
Extrapulmonary
tuberculosis.
Systemic  illness (such as
fever, night sweats,
weakness and weight loss).
Other evidence for extra
pulmonary or  disseminated
tuberculosis varies by site:
Pleural, pericardial,
peritoneal involvement,
meningitis, mediastinal or
abdominal
lymphadenopathy or
osteitis.
Discrete peripheral lymph
node Mycobacterium
tuberculosis infection
(especially cervical) is
considered a less severe
form of extrapulmonary
tuberculosis.
M. tuberculosis
isolation or
compatible
histology from
appropriate site or
radiological
evidence of miliary
tuberculosis;
(diffuse uniformly
distributed small
military shadows or
micronodules on
chest X-ray).
Extrapulmonary
cryptococcosis
(including
meningitis).
Meningitis: usually
subacute, fever with
increasing severe headache,
meningism, confusion,
behavioral changes that
Isolation of
Cryptococcus
neoformans from
extrapulmonary site
or positive
16
Clinical Event Clinical Diagnosis
Definitive
Diagnosis
respond to cryptococcal
therapy.
cryptococcal antigen
test on cerebrospinal
fluid or blood.
Chronic
cryptosporidiosis
(with diarrhea
lasting more than
one month).
No presumptive clinical
diagnosis.
Cysts identified on
modified Ziehl-
Neelsen stain
microscopic
examination of
unformed stool.
Symptomatic
HIV-associated
nephropathy.
No presumptive clinical
diagnosis.
Renal biopsy.
Table : 3
WHO immunological classification for established HIV infection 59
HIV-associated
immunodeficiency
>5 years of age (absolute
number per mm3 or % CD4+)
None or not significant > 500
Mild 350 – 499
Advanced 200 – 349
Severe <200 or <15%
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CDC Classification System for HIV Infection 56 :
The CDC categorization of HIV/AIDS is based on the lowest
documented CD4 cell count and on previously diagnosed HIV-related
conditions. If a patient had a condition that once met the criteria for
Category B but now is asymptomatic, the patient would remain in
Category B. Additionally, categorization is based on specific
conditions, as indicated below. Patients in categories A3, B3, and C1-
C3 are considered to have AIDS.
Table : 4
CDC Classification System for HIV Infection
Clinical Categories
CD4+ count
Categories
A
Asymptomatic,
Acute HIV, or
PGL
B
Symptomatic
Conditions, not A
or C
C
AIDS-
Indicator
Conditions
(1) 500
cells/μL A1 B1 C1
(2) 200-499
cells/μL A2 B2 C2
(3) <200
cells/μL A3 B3 C3
18
CDC Classification System: Category A
Consists of one or more of the following conditions listed below
in an  adolescent or adult (>13 years ) with documented infection.
Conditions listed in categories B and C must not have occurred.
x Asymptomatic HIV infection
x Persistent generalized lymphadenopathy
x Acute (primary) HIV infection with accompanying illness or
history of acute HIV infection
CDC Classification System: Category B:  Symptomatic Conditions
Category B symptomatic conditions are defined as symptomatic
conditions occurring in an HIV-infected adolescent or adult  that are not
included among conditions listed  in clinical category C and that meet
at least 1 of the following criteria:
a) They are attributed to HIV infection or indicate a defect in cell-
mediated immunity.
b) They are considered to have a clinical course or management that
is complicated by HIV infection.
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Examples include, but are not limited to, the following:
x Bacillary angiomatosis
x Oropharyngeal candidiasis (thrush)
x Vulvovaginal candidiasis, persistent or resistant
x Pelvic inflammatory disease (PID)
x Cervical dysplasia (moderate or severe)/cervical carcinoma in
situ
x Hairy leukoplakia, oral
x Idiopathic thrombocytopenic purpura
x Constitutional symptoms, such as fever (>38.5°C) or diarrhea
lasting >1 month
x Peripheral neuropathy
x Herpes zoster (shingles), involving 2 episodes or 1
dermatome
CDC Classification System: Category C: AIDS-Indicator
Conditions
x Bacterial pneumonia, recurrent (2 episodes in 12 months)
x Candidiasis of the bronchi, trachea, or lungs
20
x Candidiasis, esophageal
x Cervical carcinoma, invasive, confirmed by biopsy
x Coccidioidomycosis, disseminated or extrapulmonary
x Cryptococcosis, extrapulmonary
x Cryptosporidiosis, chronic intestinal (>1-month duration)
x Cytomegalovirus disease (other than liver, spleen, or nodes)
x Encephalopathy, HIV-related
x Herpes simplex: chronic ulcers (>1-month duration), or
bronchitis, pneumonitis, or esophagitis
x Histoplasmosis, disseminated or extrapulmonary
x Isosporiasis, chronic intestinal (>1-month duration)
x Kaposi sarcoma
x Lymphoma, Burkitt, immunoblastic, or primary central nervous
system
x Mycobacterium avium complex(MAC) or M.kansasii,
disseminated or extrapulmonary
x Mycobacterium tuberculosis , pulmonary or extrapulmonary
x Mycobacterium , other species or unidentified species,
21
x disseminated or extrapulmonary
x Pneumocystis jiroveci (formerly carinii ) pneumonia (PCP)
x Progressive multifocal leukoencephalopathy (PML)
x Salmonella septicemia, recurrent (nontyphoidal)
x Toxoplasmosis of brain
x Wasting syndrome due to HIV (involuntary weight loss >10%
of baseline body weight) associated with either chronic
diarrhea (2 loose stools per day 1 month) or chronic
weakness and documented fever 1 month
GIT MANIFESTATIONS 70 :
Highly active antiretroviral therapy (HAART) has dramatically
decreased opportunistic infections (OIs) in human immunodeficiency
virus (HIV)-infected patients. However, gastrointestinal disease
continues to account for a high proportion of presenting symptoms in
these patients. Gastrointestinal symptoms in treated patients who
respond to therapy are more likely to the result of drug-induced
complications than OI. Endoscopic evaluation of the gastrointestinal
tract remains a cornerstone of diagnosis, especially in patients with
advanced immunodeficiency, who are at risk for OI. The peripheral
22
blood CD4+ lymphocyte count helps to predict the risk of an OI, with
the highest risk seen in HIV-infected patients with low CD4 count
(<200 cells/mm3).
 ORAL THRUSH:
In a systematic literature review 65 Candidiasis was the most
common (28.6%) GIT manifestation followed by hairy leukoplakia
(9.3%), Kaposi sarcoma (2.5%), ulceration (2.5%), herpes simplex
(1.2%), papilloma (0.6%), and 4.4% had periodontal disease. Only
1.2% reported xerostomia. There were no differences in the prevalence
of oral manifestations of HIV infection between age groups, sexes,
modes of transmission and types of drug therapy.
Oropharyngeal candidiasis occurs frequently among HIV-
infected individuals, particularly those with more advanced immuno
suppression. The diagnosis of oral candidiasis is a CDC category B
diagnosis. The presence of oropharyngeal candidiasis is an indication
for initiating prophylaxis for Pneumocystis pneumonia and for initiating
antiretroviral therapy. Although HIV-related immuno suppression is
typically the most important risk factor for candidiasis, other factors
can contribute, including use of antibiotics that change normal bacterial
flora, use of corticosteroids, use of chemotherapeutic drugs, presence of
23
diabetes, decreased salivary flow rates, and wearing dentures.
Considering the strong association of HIV infection and oropharyngeal
candidiasis, HIV assessment and testing is recommended for any person
who presents with oropharyngeal candidiasis and does not have a
known risk factor for oropharyngeal candidiasis.
ESOPHAGUS:
CANDIDA:
Ana Luiza Werneck-Silva, Ivete Bedin Prado et al70 reported
Candida spp. continue to be the most common cause of OI in the
esophagus, followed by viral infection, especially CMV. Patients often
present with dysphagia, but may also develop odynophagia and/or acute
retrosternal chest pain. The presence of oral candidiasis (thrush)
suggests candidal esophagitis. On the other hand, the absence of thrush
per se does not exclude it. At endoscopy, Candida esophagitis shows a
characteristic superficial mucosal pattern: focal or confluent yellowish
white  plaques that overlie an erythematous mucosa. It is seldom related
to mucosal ulceration, which in general results from causes other than
Candida infection. Endoscopy has also been used to grade the severity
of Candida infection. They analyzed the relationship between Candida
esophagitis severity and peripheral blood CD4 cell count in a
24
prospective study of a large cohort of adult HIV-infected patients. They
suggest that even in immuno suppressed HIV-infected patients,
immunological status may play a role in limiting Candida disease in
initial grades, but seems to be irrelevant in the following progression of
the infection.  Other mechanisms, such as the local epithelial defenses,
may be involved with the development of these OIs in the GI mucosa.
DIARRHEA:
In a recent study 55 involving 388 homosexual men about 12% of
the asymptomatic men were found to have enteric pathogens.
Subsequently half of these patients were found to be HIV positive. 60%
of the symptomatic men had enteric infections, and about 65% of them
were HIV positive; this establishes a strong association between gut
infection and HIV seropositivity. Of the AIDS patients who were
asymptomatic from a gastrointestinal viewpoint 40% had evidence of
enteric infection.
In a recent study 66 in Britain 107 consecutive patients who either
had AIDS or were HIV positive were referred to a gastrointestinal
service for assessment of persistent diarrhea. This group represented
fewer than 10% of the HIV-positive patients followed up at that
institution.  Six  stool  samples  were  obtained  from  each  of  the  study
25
patients for bacteriologic assessment. Sigmoidoscopy and colonoscopy
were performed as well. Of the 71 AIDS patients 26 had
Cryptosporidium infection. An infectious cause of the diarrhea could
not be found in only 6 of the 71 patients.
The authors concluded that there was little need to implicate
noninfectious causes of diarrhea in AIDS patients. In contrast, only
one-third of the HIV-positive patients without AIDS had an identifiable
enteric cause for their diarrhea. Perhaps the enteropathy of HIV
infection is an early manifestation that assumes less importance as the
disease progresses and the host becomes more susceptible to enteric
pathogens.
In the study 67  of 143 HIV/AIDS adult patients with diarrhea, a
total of 23 cases with Cryptosporidium infection and 120 with
Cryptosporidium negative were reported during the study period. The
prevalence of cryptosporidiosis was 16.1%. The factors associated with
Cryptosporidium infection were female gender, history of diarrhea >21
days, low CD4+count and WBC count< 4,000 cells/ mm3.There was a
strong association between cryptosporidiosis and CD4+count.
26
Blanshard et al 68  have studied the course of the infection in 128
patients and identified four clinical patterns of disease: transient (28.7
per cent), chronic (59.7 per cent), fulminant (7.8 per cent) and
asymptomatic (3.9 per cent). Transient disease occurred in patients with
a wide range of CD4 lymphocyte counts, but was more common in less
immuno suppressed patients. Fulminant disease, defined by the passage
of  more  than  21  stools  /  day  from  the  time  of  presentation,  only
occurred in patients with a CD4 count of less than 50/mm3. This group
had lost more than 7 kg in weight at presentation and more commonly
had other intercurrent gastrointestinal infections. They survived for a
median of only 5 weeks, compared with 20 weeks for those with
chronic diarrhoea and 36 weeks for those with transient infection. The
survival was unaffected by any treatment other than zidovudine.
ANORECTAL DISEASES:
 Anal and perianal manifestations are frequent during HIV
infection, especially in homosexual patients. Some lesions are related to
general diseases, some others to immuno suppression. Anal herpetic
lesions are most frequently noted. Proctological examination with
microbiological and histological studies mostly offers an accurate
diagnosis.
27
LIVER DISEASE 69 :
Liver disease due to chronic hepatitis B and C is currently one of
the leading causes of morbidity and mortality among HIV-positive
patients in the developed world. Non coinfected patients with chronic
hepatitis C tend to progress to end-stage liver disease  in 20-30 years,
whereas coinfected patients have higher rates of progression. ESLD is
common in coinfected patients. The prevalence of HCV and/or HBV
coinfection is high in developed countries. Studies 69  performed in
European HIV-positive patients showed rates of 33% and 9%,
respectively while in the USA figures are very similar, 28% and 9%.
Martínez et al 69  in  Spain  analysed  the  cause  of  235  deaths  in  4471
patients (5%) on combination antiretroviral therapy (cART) from 1997
until 2004. The number of patients who died from ESLD increased
from 8% in 1997 to 41% in 2004, and in recent years this condition has
become the leading cause of death in HIV-positive patients.
Rosenthal  et  al 69  in France determined mortality due to ESLD in a
nationwide population of HIV-positive patients. The authors followed a
total of 20,940 HIV-positive patients, 4005 (19.9%) of whom were
coinfected, and showed  mortality due to ESLD represented 23.7% of
non–AIDS-related deaths. In this population 92.6% of patients who
28
died from ESLD had chronic HCV infection. A prospective,
observational study 69  of  11 cohorts  carried out  in Europe,  the United
States and Australia included 23,441 HIV-1–infected patients (22.5%
were HCV-positive) and followed them from December 1999 until
February 2004. This study showed that, of the 1246 deaths recorded,
those related to AIDS were the most frequent (31.1%), while liver
disease was the most frequent non–AIDS-related cause (14.5%). HCV
infection was shown to be an independent predictor of liver-related
death .
SPLENIC INVOLVEMENT IN TB IN HIV PATIENTS:
In a systematic literature review Ramakant  Dixit   et  al 63
reported the splenic involvement in tuberculosis seems to be more
frequent in patients with HIV infection and in disseminated form of
disease. Ultrasonography of the spleen is simple, easily available,
affordable, non-invasive, imaging technique highly useful for the
diagnosis of splenic involvement in tuberculosis. The sonographic
findings should be correlated with overall clinical presentation with
demonstration of tuberculosis at other body sites and image guided
FNAC may be considered in cases with isolates splenic involvement.
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Most of the patients (62%) were in the age group of 26-50 years.
The males were three times more commonly affected than females.
75% of the patients had fever as a presenting symptom followed by
anorexia and weight loss in 50% cases. Pain abdomen was the major
abdominal symptom seen in 62% cases followed by abdominal
distension in 12% cases. Among co-morbid illness, HIV infection was
seen in 50% cases.
On Sonography, splenic lesion commonly presents as multiple
regular hypo-echoic nodule representing tuberculoma and sometimes
irregular hypo-echoic lesion representing splenic abscess, especially in
the presence of HIV infection. Similar sonographic pattern is also being
reported in AIDS related lymphomatous involvement of spleen.
MATERIALS  AND METHODS
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MATERIALS & METHODS
Study Design:
Observational study
Study Population:
HIV  positive  patients  attending  ART  centre,  Medical  OPD,
GGH, Chennai.
Inclusion Criteria:
HIV positive patients
Exclusion Criteria:
> 60 years
Diabetic patients
On steroid therapy
Known malignancy
Organ transplant
On Chemotherapy
Ethical Clearance:
Obtained
Informed Consent:
Obtained from all patients
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Methodology:
A total of 65 patients were identified over a period of 12 months
according to the above criteria and were included in the study. Of there
only 40 patients turned up for follow up and participated in the study.
A questionnaire prepared noted the age, sex, address, primary
complaints, GIT symptoms, medical illness such as SHT, psychiatric
disorders, substances abuse, smoking, alcoholism and other complaints
if any.
Clinical examination included a detailed examination from head
to foot, examination of cardiac, respiratory, GIT and nervous system.
Perianal, per rectal, per vaginal examination (in females) was
done.
Laboratory Investigations:
The following investigations are done in all patients during their
first visit:
Blood sugar, urea, creatinine
Liver function test
Complete blood count
HBsAg
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Anti HCV
CD4 count
CXR, sputum AFB
USG abdomen and pelvis
During subsequent visit:
1. Stool for ova, cyst, occult blood and stool culture
2. OGD scopy
If needed basis,
 CT abdomen and  pelvis plain and contrast
 Ascitic fluid analysis including AFB culture
 Pleural fluid analysis including AFB culture
 Sputum AFB stain
Lumbar puncture and CSF analysis including AFB  culture, India
ink preparation for Cryptococcus
Nerve Conduction Study
MRI Brain with MRA & MRV
Tzanck smear
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Table : 5
Parameters
S.No. Parameter Method
1. Complete blood count Automated flow cytometry
2. ESR Westergren method
3. Urea GLDH/urease
4. Creatinine Picrate method
5. Serum albumin Bromocresol green
6. Serum bilirubin Calorimetric endpoint diazo
7. Total Protein Biuret method
8. Stool for parasites Conc method (sat. saline
floatation) & iodine, modified ZN
stain
9. Occult blood in stools Standard guaiac test
10. HBsAg Rapid detection kit
11. Anti HCV ELISA
12. CD4+ count Fluorescence Activated cell Sorter
(FACS)
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Statistical Analysis:
Data analysis was done with use of SPSS, version 13. Descriptive
statistics were used to calculate the frequency, mean, and standard
deviation. To examine the linear trend of the proportions, trend chi-
square was used and to find the test of association chi-square was
computed.
Financial support:
Nil
Conflicts of interest:
None
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Table : 6
Normal Values
Hemoglobin M: 13.3 – 16.2 gms% F: 12.0 –
15.8gms%
PCV M:38.8 – 46.4 35.4 – 44.4
Total Count 3.54 – 9.06 x 103/mm3
Platelet Count 165 – 415 x 103/mm3
MCV 80 – 100 fL
MCHC 32.3 – 35.9g/dL
MCH 26.7 – 31.9 pg/cell
ESR M:0 – 15mm/hr F:0-20mm/hr
Reticulocyte count M:0.8 – 2.3% F:0.8 – 2.0%
Creatinine M:0.6 – 1.2mg/dl F:0.5 – 0.9mg/dl
BUN 7 – 20 mgs/dl
Total Bilirubin 0.3 – 1.3 mgs/dl
Direct Bilirubin 0.1 – 0.4 mgs/dl
SGOT 12 – 38 U/L
SGPT 7 – 41 U/L
Se.Alkaline phosphatase 33 – 96 U/L
Total Protein 6.7 – 8.6 gms/dl
Se.Albumin 3.5 – 5.5 gms/dl
HBsAg Negative
Anti HCV Negative
CD 4+ count 500 – 1500 cells per mm3
 OBSERVATION
AND
RESULTS
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OBSERVATION & RESULTS
STUDY POPULATION CHARACTERISTICS:
TABLE : 7
SEX DISTRIBUTION
SEX NO. OFPATIENTS PERCENTAGE P value
Male 26 65%
Female 14 35%
0.058
FIGURE : 1 SEX-WISE DISTRIBUTION OF PATIENTS
26
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In our study, 26 (65%) patients were male, and 14 (35%) patients
were female, though it is not statistically significant with a P value of
0.058.
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TABLE : 8
AGE DISTRIBUTION
AGE
GROUP
NO. OF
PATIENTS MALE FEMALE PERCENTAGE
15  - 25 1 0 1 2.5%
26 – 35 17 11 6 42.5%
36 – 45 15 10 5 37.5%
46 – 60 7 5 2 17.5%
FIGURE : 2 AGE WISE DISTRIBUTION OF PATIENTS
15
17
17
15-25
26-35
36-45
46-60
Among 40 patients in our study 32(80%) were in the age group
of  26  to  45  years,  which  is  statistically  significant  with  a  P  value  of
0.001 The Mean Age of the patients included in the study was 42.55
mean years,  with S.D. of 3.178  years.
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TABLE : 9
WHO CLINICAL STAGING
STAGE NO. OFPATIENTS MALE FEMALE PERCENTAGE
1 1 0 1 4%
2 1 0 1 4%
3 4 1 3 12%
4 14 12 2 56%
Not
specified 5 4 1 20%
FIGURE : 3 WHO CLINICAL STAGING
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Among 25 new patients in our study 12 (48%) male patients were
in WHO stage 4 which is statistically significant with a P value of 0.04.
4 (16%) of patients were in WHO stage 3. 5(20%) of patients not met
the WHO clinical staging criteria of HIV.
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TABLE : 10
 WHO IMMUNOLOGICAL CLASSIFICATION
CD 4+
COUNT
MALE FEMALE PERCENTAGE
>500 0 0 0%
350-499 0 1 4%
200-349 0 2 8%
<200 17 5 88%
FIGURE : 4 WHO IMMUNOLOGICAL CLASSIFICATION
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Among 25 new patients in our study 2(8%) patients were in
advanced immunosuppression when presented for the first  time for
HIV diagnosis, 22(88%) patients were in severe  immunosuppression,
which is statistically significant with a P value of 0.027.
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TABLE : 11
CDC CLASSIFICATION
CDC MALE FEMALE PERCENTAGE
A1 0 0 0%
A2 0 0 0%
A3 0 1 4%
B1 0 0 0%
B2 0 3 12%
B3 2 2 16%
C1 0 0 0%
C2 0 0 0%
C3 12 2 56%
Not specified 3 0 12%
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FIGURE : 5 CDC CLASSIFICATION
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In our study 14(56%) patients were belong to CDC classification
C3 at the time of diagnosis, which is statistically significant with a P
value of 0.014
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TABLE : 12
 SYSTEM INVOLVED AT THE TIME OF DIAGNOSIS
SYSTEM NO. OF PATIENTS PERCENTAGE
GIT 13 52%
CNS 5 20%
LYMPH 4 16%
RS 1 4%
GENITAL 1 4%
FEVER 1 4%
FIGURE : 6 SYSTEM INVOLVED AT THE TIME OF
DIAGNOSIS
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In our study GIT (52%) is the most common system involved at
the time of diagnosis of HIV infection, which is statistically significant
with a P value of 0.001 followed by central nervous system and
lymphatic system.
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TABLE : 13
GIT SYMPTOMATOLOGY
SYMPTOM NO. OF PATIENTS PERCENTAGE
Dys & odynophagia 4 17.39%
Abdominal pain 5 29.73%
Abdominal distension
& fullness
5 29.73%
Abdominal mass 1 4.36%
Diarrhea 9 31.93%
Jaundice 1 4.36%
Painful defecation 2 8.69%
Anasarca 1 4.36%
FIGURE : 7 GIT SYMPTOMATOLOGY
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In  our  study  diarrhea  (31.93%)  is  the  most  common  GIT
symptom, which is statistically significant with a P value of 0.025,
followed by abdominal pain, fullness, distension & dysphagia,
odynophagia.
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TABLE : 14
ENDOSCOPY FINDINGS
FINDING NO. OF PATIENTS PERCENTAGE
Esophageal
candidiasis
4 50%
GERD 1 12.5%
Esophageal varices 2 25%
Pan gastritis 1 12.5%
FIGURE : 8 ENDOSCOPY FINDINGS
4
1
2
1
Esophageal candidiasis
GERD
Varices
Pangastritis
In 8 patients underwent UGI endoscopy 4 (50%) patients had
esophageal candidiasis  followed by esophageal varices in 2 (25%)
patients.
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TABLE : 15
ESOPHAGEAL CANDIDIASIS & CD4+COUNT
CD4+COUNT NO. OF PATIENTS PERCENTAGE
>500 0 0%
350-499 0 0%
200-349 0 0%
<200 4 100%
FIGURE : 9 ESOPHAGEAL CANDIDIASIS AND CD4+COUNT
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In our study all patients with esophageal candidiasis had
CD4+count <200 cells / mm3 which is statistically significant with a P
value of <0.001.
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TABLE : 16
USG FINDINGS
FINDING NO. OF PATIENTS PERCENTAGE
Hypo echoic lesions
spleen
7 17.5%
Intra abdominal
lymph adenopathy
5 12.5%
DCLD 2 5%
Cholecystitis 2 5%
Ascites 4 10%
Echogenic kidneys 1 2.5%
Intra abdominal mass 1 2.5%
Splenomegaly 2 5%
FIGURE : 10 USG FINDINGS
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In our study hypoechoic lesions in spleen was seen in 7(17.5%)
patients, though it is not statistically significant with a P value of 0.154
which is followed by intra abdominal lymphadenopathy & ascites each
in 5 (12.5%) patients.
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TABLE : 17
HYPOECHOIC LESIONS IN SPLEEN
ASS  FINDING NO. OF PATIENTS PERCENTAGE
Intra abdominal
lymphadenopathy
5 71.4%
Ascites 4 57.14%
Pleural effusion 3 42.85%
Splenomegaly                  1 14.28
Intra abdominal mass 1 14.28
Gastric wall
thickening
1 14.28
FIGURE : 11 HYPOECHOIC LESIONS IN SPLEEN
5
4
3
1
1
1
71.4
57.14
42.85
14.28
14.28
14.28
0 20 40 60 80
Intra abdominal
lymphadenopathy
Ascites
Pleural effusion
Splenomegaly
Intra abdominal
mass
Gastric  wal l
thickening
Percentage
No of patients
Intra abdominal lymphadenopathy(71.4%) is the common
associated finding in patients with hypoechoic lesions in spleen, which
is not statistically significant with a P value of 0.287  followed by
ascites & pleural effusion.
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TABLE : 18
ASSOCIATED DISEASES &  HYPOECHOIC
LESIONS IN SPLEEN
DIAGNOSIS NO. OF PATIENTS PERCENTAGE
TB 5 57.14%
Lymphoma 1 14.28%
Candidiasis 1 14.28%
FIGURE : 12 ASSOCIATED DISEASES &  HYPOECHOIC
LESIONS IN SPLEEN
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In our study TB is the most common associated disease in
patients with  spleen hypoechoic lesions which is not statistically
significant with a P value of 0.102.
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TABLE : 19
CAUSES OF DIARRHEA
DIAGNOSIS NO. OF PATIENTS PERCENTAGE
Pathogen negative 4 44.44%
Cryptosporidiosis 4 44.44%
E.H cyst 1 11.11%
FIGURE : 13 CAUSES OF DIARRHEA
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In our study pathogen negative diarrhea & cryptosporidiosis
contributed to 8(88.88%) cases of diarrhea, which is not statistically
significant with a P value of 0.368.
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TABLE : 20
CRYPTOSPORIDIOSIS & CD4+COUNT
CD4+COUNT NO. OF PATIENTS PERCENTAGE
<50 1 25%
51-100 3 75%
101-200 0 0%
>200 0 0%
FIGURE : 14 CRYPTOSPORIDIOSIS & CD4+COUNT
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3
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<50
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In our study all cases of cryptosporidiosis had CD4+count <100,
which is not statistically significant with a P value of 0.317
Fig: 15 USG Abdomen and Pelvis showing few tiny calculi in the GB
with features of chronic cholecystitis/ a lobulated inhomogenously hypo
echoic lesion 14.4/13/12cm in size with ill defined margins in the right
lower abdomen with pre and paraaortic lymphadenopathy/ multiple
hypo echoic lesions in spleen.
Fig: 17 Esophageal candidiasis in OGD scopy.
Fig: 16 Oocyst of Cryptosporidium parvum on AFB strain in stool analysis.
DISCUSSION
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DISCUSSION
CHARACTERISTICS OF STUDY POPULATION:
Most of our patients in the study group were males (65%).
Females contributed to 35% of patients. Most of our patients in the
study group were in the age group of 26 to 35 years (42.5%) and
immediately followed by patients in the age group of 36 to 45 years
(37.5%).
56% of patients in our study group were in WHO Clinical Stage
4  at  the  time  of  diagnosis.  20%  of  patients  had  clinical  disease  not
represented in WHO Clinical Stages. The diseases are decompensated
chronic liver disease, acute inflammatory demyelinating
polyneuropathy, cerebrovascular accident.
88% of patients in our study group were in severe immuno
deficiency in  WHO immunological classification at the time of
diagnosis. 56% of patients in our study group were in CDC
Classification  System  C3  at  the  time  of  diagnosis.  Similar  to  WHO
Clinical Staging  system 12% of patients were not represented in this
classification also. The diseases are decompensated chronic liver
disease, cerebrovascular accident.
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GASTRO INTESTINAL  INVOLVEMENT :
Gastrointestinal symptoms contributed to the diagnosis of HIV
infection / AIDS in 52% of our cases followed by central nervous
system in 20%, lymphatic system in 16%. Unexplained fever,
respiratory system, genital system each contributed to 4%.
In our study 57.5% of patients had gastro intestinal symptoms. In
that diarrhea is the most common (39.13%) symptom, followed by
abdominal pain, fullness, distension (29.73%) & dysphagia,
odynophagia (17.39%). Both nausea and vomiting were excluded.
 Similar results were observed in a study done by Joseph Bick et
al 62 . He reported that worldwide diarrhea is the most common cause of
morbidity and mortality in those who are HIV infected.
In our study endoscopy done for 8 patients who had major UGI
symptoms. All patients with the history of dysphagia and odynophagia
had esophageal candidiasis. All the cases were associated with oral
thrush.Similar results were observed in the following study. Ana Luiza
Werneck-Silva, Ivete Bedin Prado et al 70  reported  Candida spp.
continue to be the most common cause of OI in the esophagus,
followed by viral infection, especially CMV. Presence of oral thrush
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suggests esophageal candidiasis. On the other hand, the absence of
thrush per se does not exclude it.
STOOL ANALYSIS:
In patients with diarrhea, cryptosporidiosis and pathogen
negative diarrhea contributed to 44.44% of cases each.11.11%of cases
had amoebiasis.
 In a recent study 66 in Britain 107 consecutive patients who either
had AIDS or were HIV positive were referred to a gastrointestinal
service for assessment of persistent diarrhea. This group represented
fewer than 10% of the HIV-positive patients followed up at that
institution.  Six  stool  samples  were  obtained  from  each  of  the  study
patients for bacteriologic assessment. Sigmoidoscopy and colonoscopy
were performed as well. Of the 71 AIDS patients 26 had
Cryptosporidium infection. An infectious cause of diarrhea could not be
found in only 6 of the 71 patients.
The authors concluded that there was little need to implicate
noninfectious causes of diarrhea in AIDS patients. In contrast, only
one-third of the HIV-positive patients without AIDS had an identifiable
enteric cause for their diarrhea. Perhaps the enteropathy of HIV
infection is an early manifestation that assumes less importance as the
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disease progresses and the host becomes more susceptible to enteric
pathogens.
USG ABDOMEN&PELVIS:
In our study 17.5% patients had hypo echoic lesions in spleen
and was the common abnormality in USG followed by intra abdominal
lymphadenopathy in 12.5% of patients. In those who had hypo echoic
lesions in spleen intra abdominal lymphadenopathy was the most
common associated finding followed by ascites and pleural effusion.
TB was the most common associated diseases in patients with spleen
hypo  echoic lesions. Non Hodgkins lymphoma and candidiasis were
the  other  diseases.  On  follow  up  one  of  the  five  patients  with
tuberculosis had expired due to liver failure.
Similar  results  were  observed  in  a  study  done  by Ramakant
Dixit et al 63 . They  observed  50%  of  the  patients  of  TB  involving
spleen were HIV patients.
In our study 2 (8.69%) patients had liver involvement in the form
of decompensated chronic liver disease. One patient had coexistent
HCV infection. He was a  I.V. drug  abuser. Another patient had
coexistent alcohol abuse with percutaneous exposure to shaving
instrument.
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LIMITATIONS OF THE STUDY
x The major limitation of our study is small number of subjects we
have included in our study.
x Colonoscopy was not done in our patients. So substantial number
of  structural causes of diarrhea missed in our study.
x Spleen hypo echoic lesions were not aspirated and
microbiological tissue diagnosis was not made. This is one of the
major limitation of the study.
CONCLUSION
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                                     CONCLUSION
x HIV infection more commonly seen in males (65%) when
compared to females(35%).
x HIV infection is diagnosed most commonly in the age group
26-45 years.
x At  the  time  of  diagnosis  56%  of  patients  are  in  WHO  Clinical
Stage 4. 88% of patients are in WHO Immunological
Classification Severe immuno suppression. 56% of patients are in
CDC Classification System C3. Cerebro vascular disease and
decompensated chronic liver disease are not represented in WHO
Clinical and CDC Classification System. AIDP also not
represented in WHO Clinical Staging.
x GIT is  the  most  common (52%)  system involved  at  the  time  of
diagnosis of HIV infection followed by central nervous system
and lymphatic system.
x Diarrhea is the most common (31.93%) GIT symptom followed
by abdominal pain, fullness, distension & dysphagia,
odynophagia.
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x All patients with esophageal candidiasis had CD4+count <200
cells/mm3.All of them had oral thrush.
x In USG hypoechoic lesions in spleen is the most common
abnormality  followed by intra abdominal lymphadenopathy &
ascites.
x In HIV patients TB is the most common associated  disease in
patients with hypoechoic lesions in spleen.
x Pathogen negative diarrhea & cryptosporidiosis are the common
(88.88%) causes of diarrhea. All cases of cryptosporidiosis had
CD4+count <100 cells/mm3
x Hence  this  study  concludes  that  sometimes  the  first  clue  that  a
previously undiagnosed patient is HIV-infected is the presence of
an HIV-associated gastrointestinal condition. So it is mandatory
to investigate for HIV/AIDS routinely in all patients admitted for
GIT complaints.
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AREAS OF FUTURE RESEARCH
More efficient programs for early diagnosis of HIV to prevent
transmission are urgently required.
Spleen involvement in HIV patients needs extensive research
regarding etiology, response to treatment with ATT in patients having
associated tuberculosis, antifungal therapy in patients having associated
candidiasis, its impact on overall prognosis of these patients.
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ANNEXURES
PROFORMA
GIT INVOLVEMENT IN NEWLY DIAGNOSED HIV PATIENTS
Name :
Age : Sex : OP/IP Number :
Address :
Ph.No :
New/Old  patient :                                   CD4+ count :
PRESENTING COMPLAINTS :
SYSTEM INVOLVED :
GIT COMPLAINTS :                                   PAST HISTORY :
 1.Dysphagia                                                 1.ART
 2.Odynophagia                                             2.ATT
 3.Abdominal pain                                         3.SHT
 4.Abdominal distension&fullness                4.PT
 5.Jaundice                                                     5.Psychiatric illnes
 6.Diarrhea                                                     6.DM
 7.Painful defecation
 8.Anasarca
PERSONAL HISTORY :
 1.Smoking
 2.Alcoholism
 3.IV Drug User
 4.Mode of sexual contact
EXAMINATION :
Pallor : Jaundice :
Lymphadenopathy : Cyanosis :
Clubbing : Pedal edema :
Vital Signs : BP-    PR-       Temp-        RR-
CVS :
RS :
Abdomen :
CNS :
Genitalia :
Per rectal/Per vaginal examination(in females) :
INVESTIGATIONS :
CBC : HB% : TC : P : L : E : B : M :
          Platelets :
LFT : TB : DB : SGOT/SGPT : ALP :
         Total Protein/Albumin
HBsAg & Anti HCV: Stool  Analysis :
USG Abdomen&Pelvis : OGD Scopy:
PATIENT CONSENT FORM
Gastro intestinal involvement in newly diagnosed HIV patients
Study centre                : Govt.General hospital, MMC, Chennai
Patient’s name :
Patient’s age :
Identification number :
 I confirm that I have understood the purpose of the procedures of   the
above study. I have had the opportunity to ask questions and all my questions have
been answered satisfactorily.
           I understand that my participation in the study is entirely voluntary and that
I  am  free  to  withdraw  from  the  study  at  any  time  without  my  legal  rights  being
affected
I understand that sponsors of the study, others working on sponsor’s behalf,
the ethics committee and the regulatory authorities will not need my permission
to look at my health records both in respect of current study and any future
research that may be conducted in relation to it; even if I withdraw from the study I
agree to this access. However I understand that my identity will not be revealed in
any information released to third parties unless required by law. I agree not to
restrict the use of any data or results arising from the study.
I agree to take part in the above the study an to comply with the instructions
given during the study and inform about any change in my health status to the
investigator.
I hereby give permission to undergo complete clinical examination
and investigations as part of the study.
Signature of the patient
Patient’s name and address place date
Signature of the investigator
Investigator’s name place  date



